<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248816</url>
  </required_header>
  <id_info>
    <org_study_id>834574</org_study_id>
    <secondary_id>5P30AG03456-10</secondary_id>
    <nct_id>NCT04248816</nct_id>
  </id_info>
  <brief_title>Hepatocellular Carcinoma Surveillance in Cirrhotics</brief_title>
  <official_title>Increasing Surveillance Rates for Hepatocellular Carcinoma Among Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-arm pilot randomized controlled trial applying behavioral economic approaches&#xD;
      (opt-out framing and financial incentives) to encourage patients with liver cirrhosis to&#xD;
      complete regular surveillance ultrasounds which may allow for earlier diagnosis of and better&#xD;
      outcomes for hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a substantial burden of HCC-related morbidity and mortality: The age-adjusted&#xD;
      incidence rates of HCC have tripled in the US since the 1980s due to the burden of hepatitis&#xD;
      C virus (HCV) and the epidemic of non-alcoholic fatty liver disease (NAFLD). The overwhelming&#xD;
      majority of HCC in the US occurs in the setting of cirrhosis. Early diagnosis of HCC dictates&#xD;
      survival: The American Association for the Study of Liver Diseases (AASLD) recommends&#xD;
      biannual HCC surveillance for all patients with cirrhosis using an abdominal ultrasound.&#xD;
      These guidelines seek to maximize early diagnosis of HCC which leads to earlier detection and&#xD;
      improved survival because early-stage HCC is curable, with 70% 5-year survival compared to 5%&#xD;
      in advanced disease.&#xD;
&#xD;
      HCC surveillance rates are suboptimal: Despite longstanding published guidelines for HCC&#xD;
      surveillance, adherence is low, with surveillance rates ranging from 15-30% in the US. Two&#xD;
      RCTs have tested interventions to increase HCC surveillance, including electronic reminders&#xD;
      for primary care providers and mailed reminders (with or without navigators), but neither has&#xD;
      been scalable, produced durable responses, or increased surveillance rates above 50%.&#xD;
&#xD;
      This is a 3-arm pilot randomized controlled trial applying behavioral economic approaches&#xD;
      (opt-out framing and financial incentives) to encourage patients with liver cirrhosis to&#xD;
      complete regular surveillance ultrasounds which may allow for earlier diagnosis of and better&#xD;
      outcomes for hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCC screening completion</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who have a surveillance abdominal ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCC screening method</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who have any hepatocellular carcinoma surveillance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">615</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opt-out</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facilitated outreach and opt-out framing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opt-out + Incentive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facilitated outreach and opt-out framing plus a financial incentive</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Subjects will receive outreach through their providers as is standard of care.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Opt-out</intervention_name>
    <description>Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.</description>
    <arm_group_label>Opt-out</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Opt-out + Incentive</intervention_name>
    <description>Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.</description>
    <arm_group_label>Opt-out + Incentive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are 18+ years old&#xD;
&#xD;
          -  Current diagnosis of cirrhosis or advanced fibrosis&#xD;
&#xD;
          -  1 or more visits to a Penn Gastroenterology/Hepatology practice in the preceding two&#xD;
             years&#xD;
&#xD;
          -  Currently followed by Penn Gastroenterology/Hepatology&#xD;
&#xD;
          -  Must live in the Philadelphia Metropolitan Statistical Area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of HCC or other liver carcinoma diagnosis&#xD;
&#xD;
          -  History of liver transplant&#xD;
&#xD;
          -  Completed HCC screening within the past 7 months&#xD;
&#xD;
          -  Have a future screening scheduled&#xD;
&#xD;
          -  Have a different screening modality recommended by their physician (MRI, CT, etc.)&#xD;
&#xD;
          -  Patients with metastatic cancer&#xD;
&#xD;
          -  Patients receiving hospice care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shivan Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Shivan J Mehta</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Behavioral Economics</keyword>
  <keyword>Screening</keyword>
  <keyword>Outreach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

